Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02249429 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
A Phase 2 study of Lymphoma, Malignant, sponsored by PIQUR Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 12
- Study locations
NCT02249429: Completed Phase 2 study of Lymphoma, Malignant, sponsored by PIQUR Therapeutics.
NCT02249429 is a Phase 2 study of Lymphoma, Malignant that has completed, run by PIQUR Therapeutics. The registered enrollment target is 53 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower). The trial reports 12 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02249429, a Phase 2 study of Lymphoma, Malignant, has completed, sponsored by PIQUR Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 12
- Study locations
Study Summary
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.
Primary Outcome
Radiological lymphoma Evaluation (CT or other indicated according to institutional standard practice), clinical examination and bone marrow biopsy
Conditions Studied
Interventions
- DRUG bimiralisib
Study Locations (12)
Other
- University Clinical Center Republic of Srpska - Banja Luka
- University Clinical Center Sarajevo - Sarajevo
- Univeristy Hospital Haifa - Haifa
- Institute for Oncology and radiology of Serbia - Belgrade
- Clinical Center Kragujevac - Kragujevac
- Clinical Center Nis - Niš
- Guy's Hospital - London
- Royal Marsden NHS Foundation Trust - London
- University College Hospital London - London
- Churchill Hospital - Oxford
New York
- Weill Cornell Medicine - New York
Paris
- Insitute Curie - Saint-Cloud
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 2 |
What the finished NCT02249429 record still lists
NCT02249429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Lymphoma, Malignant appearing as the primary indexed condition, and to 1 intervention - of which bimiralisib is the first listed.
NCT02249429 lists 12 locations in 3 states (Other, New York, Paris).
Frequently Asked Questions
What is clinical trial NCT02249429 about?
NCT02249429 is a clinical study titled "Open-Label, Non Randomized Phase 2 Study With Safety Run-In". The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or r...
What is the current status of trial NCT02249429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2015-05. Estimated completion is 2018-09-11.
What conditions does trial NCT02249429 study?
This clinical trial studies the following conditions: Lymphoma, Malignant.
What interventions are being tested in trial NCT02249429?
The interventions under investigation include: bimiralisib (DRUG).
Who is sponsoring clinical trial NCT02249429?
This trial is sponsored by PIQUR Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02249429 being conducted?
This trial has 12 study locations across New York, Paris. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02249429's enrollment target sits among peer trials
53 1171st of 2000 higher than 820 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia